Evidence map›Paper›PMID 42436341›Full record

ArticleHeredity2026

Efficiency under epistasis of haplotype-based genomic selection for pure line breeding.

Jean Paulo Aparecido Silva, José Marcelo Soriano Viana

Abstract read
In one paragraph

Article in Heredity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jean Paulo Aparecido SilvaDepartment of General Biology, Federal University of Viçosa, Viçosa, MG, Brazil.
José Marcelo Soriano VianaDepartment of General Biology, Federal University of Viçosa, Viçosa, MG, Brazil. jmsviana@ufv.br.ORCID http://orcid.org/0000-0002-5063-4648

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haplotype-based genomic selection is considered a more efficient alternative for genomic selection under epistasis. We evaluated the efficacy of haplotype-based genomic selection under seven digenic epistasis types and the significance of including the additive x additive (AxA) effect in selection in pure line breeding. We simulated a genome composed of 10 chromosomes of 100 cM, including 1000 genes and 49,825 SNPs. We assumed positive dominance and 30% epistatic genes. We performed genomic selection using haplotypes of sizes 3, 6, and 9. We also processed low-cost genomic selection using 20% of the SNPs. We assessed selection efficacy using realized total genetic gain. We also evaluated the correlation between prediction accuracy and realized genetic gain and the decrease in genotypic variance over generations. Regardless of the epistasis type and SNP density, genomic selection was an efficient procedure for the development of superior pure lines. There was no effect of haplotype size on the efficacy of genomic selection. Under no selection, the AxA genetic value was negatively correlated with low magnitude ( < -0.25) with the number of favorable genes. Under selection, the inclusion of the predicted AxA value for selection did not increase the selection efficacy. Haplotype- and SNP-based genomic selection processes were equally efficient. Compared with traits determined only by additive and dominance gene effects, epistasis can decrease the total genetic gain. Under epistasis, there was a highly positive correlation between genetic gain and prediction accuracy. There was no difference between genomic selection procedures in terms of the decrease in genotypic variance.

Indexed as

BreedingEpistasis, GeneticHaplotypesSelection, GeneticComputer SimulationGenotypeModels, GeneticPolymorphism, Single Nucleotide

Identifiers

PMID42436341
PMCPMC13612590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.